{
  "drug_name": "Naproxen",
  "drug_class": "Nonsteroidal Anti-inflammatory Drug [EPC]",
  "uses": "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: \u2022 rheumatoid arthritis \u2022 osteoarthritis \u2022 ankylosing spondylitis \u2022 Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of: \u2022 tendonitis \u2022 bursitis \u2022 acute gout the management of: \u2022 pain \u2022 primary dysmenorrhea Naproxen tablets and naproxen sodium tablets are non-steroidal anti-inflammatory drugs indicated for: the relief of the signs and symptoms of: \u2022 rheumatoid arthritis \u2022 osteoarthritis \u2022 ankylosing spondylitis \u2022 polyarticular juvenile idiopathic arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of: \u2022 tendonitis \u2022 bursitis \u2022 acute gout the management of: \u2022 pain \u2022 primary dysmenorrhea",
  "dosage_info": "2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis Naproxen tablets 250 mg (one-half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one-half tablet) 550 mg twice daily The dose may be adjusted up or down depending on the clinical response of the patient. In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/ day for up to 6 months. Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets may not allow for the flexible dose titration needed in pediatric patients with polyarticular juvenile idiopathic arthritis. A liquid formulation may be more appropriate. Recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses. Dosing with naproxen tablets is not appropriate for children weighing less than 50 kilograms. Management of Pain, Primary Dysmenorrhea,...",
  "common_side_effects": "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: \u2022 Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ] \u2022 GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ] \u2022 Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ] \u2022 Hypertension [ see Warnings and Precautions ( 5.4 ) ] \u2022 Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ] \u2022 Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ] \u2022 Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ] \u2022 Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ] \u2022 Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema. (...",
  "serious_side_effects": "5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. ( 5.3 ) Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure. ( 5.4 , 7 ) Heart Failure and Edema: Avoid use of naproxen tablets and naproxen sodium tablets in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. ( 5.5 ) Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of naproxen tablets and naproxen sodium tablets in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function. ( 5.6 ) Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction...",
  "contraindications": "4 CONTRAINDICATIONS Naproxen tablets and naproxen sodium tablets are contraindicated in the following patients: \u2022 Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see Warnings and Precautions ( 5.7 , 5.9 ) ] \u2022 History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [ see Warnings and Precautions ( 5.7 , 5.8 ) ] \u2022 In the setting of coronary artery bypass graft (CABG) surgery [ see Warnings and Precautions ( 5.1 ) ] \u2022 Known hypersensitivity to naproxen or any components of the drug product ( 4 ) \u2022 History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs ( 4 ) \u2022 In the setting of CABG surgery ( 4 )",
  "warnings": "WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events \u2022 Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions ( 5.1 ) ]. \u2022 Naproxen tablets and naproxen sodium tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraindications ( 4 ), Warnings and Precautions ( 5.1 ) ]. Gastrointestinal Bleeding, Ulceration, and Perforation \u2022 NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at...",
  "source": "OpenFDA API"
}